dinona inc
3SBio Licenses DiNonA’s Anti-Leukemia Treatment
3SBio and DiNonA will develop Leukotuximab, an anti JL-1 antibody indicated for the treatment of acute leukemia.
3SBio and DiNonA will develop Leukotuximab, an anti JL-1 antibody indicated for the treatment of acute leukemia.